CLASS II Drug recall · Reported 9 May 2018 · FDA Enforcement Report
Levofloxacin in 5% Dextrose Injection, 750 mg Levofloxacin recalled
AuroMedics Pharma is recalling Levofloxacin in 5% Dextrose Injection, 750 mg Levofloxacin (5 mg/mL) in of 5% Dextrose, distributed nationwide in the US. The recall was initiated on 27 Mar 2018 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0709-2018
- FDA event ID
- 79772
- Recalling firm
- AuroMedics Pharma, East Windsor, NJ
- Brand
- Levofloxacin
- Manufacturer
- Eugia US LLC
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- 27 Mar 2018
- FDA classified
- 3 May 2018
- Reported
- 9 May 2018
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Mold
- Drug class
- Antibiotics
Timeline
| 27 Mar 2018 | Recall initiated by company | |
| 3 May 2018 | Classified by FDA | +37 days |
| 9 May 2018 | Published in enforcement report | +6 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap
Product as listed by the FDA
Levofloxacin in 5% Dextrose Injection, 750 mg Levofloxacin (5 mg/mL) in 150 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for AuroMedics Pharma, LLC, NDC 55150-245-52
Where it was distributed
US Nationwide
Questions about this recall
Why was it recalled?
Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap
Which lots are affected?
Lot/Batch #'s: CLF160012, CLF160014 exp July 2018; CLF170007, CLF170008, CLF170009, CLF170010, CLF170011, CLF170012, CLF170013 exp February 2019; CLF170014, CLF170015, CLF170016 exp March 2019; CLF170017, CLF170018, CLF170019, exp April 2019; CLF170020, CLF170021, CLF170022 exp May 2019; CLF170035, CLF170036, CLF170037, CLF170038 exp August 2019; CLF170048, CLF170049, CLF170050, CLF170051, CLF170052 exp September 2019
Where was it sold?
US Nationwide
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
Other products in this recall event
6 other products · FDA event 79772| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| CLASS II | Levetiracetam in 0.54% Sodium Chloride Injection recalledLevetiracetam | AuroMedics Pharma | Mold | Nationwide | |
| CLASS II | Levetiracetam in 0.82% Sodium Chloride Injection recalledLevetiracetam | AuroMedics Pharma | Mold | Nationwide | |
| CLASS II | Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin recalledLevofloxacin | AuroMedics Pharma | Mold | Nationwide | |
| CLASS II | Levofloxacin in 5% Dextrose Injection, 500 mg Levofloxacin recalledLevofloxacin | AuroMedics Pharma | Mold | Nationwide | |
| CLASS II | Linezolid Injection 600 mg recalled by AuroMedics PharmaLinezolid | AuroMedics Pharma | Mold | Nationwide | |
| CLASS II | Levetiracetam in 0.75% Sodium Chloride Injection recalledLevetiracetam | AuroMedics Pharma | Mold | Nationwide |
More recalls from AuroMedics Pharma
All 36| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Fondaparinux Sodium Injection, USP, 7.5 mg per, Single Dose recalledFondaparinux Sodium | AuroMedics Pharma | Potency & Assay | Nationwide |
| Drug | CLASS II | Acyclovir Sodium Injection, 500mg/ (50mg/mL) Single Dose Vial recalledAcyclovir Sodium | AuroMedics Pharma | Particulate Matter | Nationwide |
| Drug | CLASS III | Tranexamic Acid Injection, USP, 1000mg recalled by AuroMedics PharmaTranexamic Acid | AuroMedics Pharma | Particulate Matter | Nationwide |
| Drug | CLASS I | Polymyxin B for Injection USP per Vial vials recalledPolymyxin B | AuroMedics Pharma | Particulate Matter | Nationwide |
| Drug | CLASS II | Acetaminophen Injection 1,000 mg recalled by AuroMedics PharmaAcetaminophen | AuroMedics Pharma | Other | Nationwide |
Other Levofloxacin recalls
All 19| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Levofloxacin Oral Solution, 25 mg/mL recalled by Akorn | Akorn | Potency & Assay | Nationwide |
| Drug | CLASS II | Levofloxacin Ophthalmic Solution recalled by Akorn | Akorn | Potency & Assay | Nationwide |
| Drug | CLASS II | Levofloxacin Injection 500mg/ (25 mg/mL), For Intravenous Infusion recalled | Akorn | Potency & Assay | Nationwide |
| Drug | CLASS III | Levofloxacin Tablets, USP 500 mg recalled by Macleods Pharma Usa | Macleods Pharma USA | Packaging Defects | Nationwide |
| Drug | CLASS II | Levofloxacin Tablets, 500 mg unit dose recalledLevofloxacin | Mckesson Medical-Surgical Inc. Corporate Office | Manufacturing (CGMP) Deviations | Nationwide |